"Markov Chains" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A stochastic process such that the conditional probability distribution for a state at any future instant, given the present state, is unaffected by any additional knowledge of the past history of the system.
| Descriptor ID |
D008390
|
| MeSH Number(s) |
E05.318.740.600.500 E05.318.740.996.500 G17.830.500 N05.715.360.750.625.500 N05.715.360.750.770.500 N06.850.520.830.600.500 N06.850.520.830.996.500
|
| Concept/Terms |
Markov Chains- Markov Chains
- Chains, Markov
- Markov Process
- Markov Processes
- Process, Markov
- Processes, Markov
- Markov Chain
- Chain, Markov
|
Below are MeSH descriptors whose meaning is more general than "Markov Chains".
Below are MeSH descriptors whose meaning is more specific than "Markov Chains".
This graph shows the total number of publications written about "Markov Chains" by people in this website by year, and whether "Markov Chains" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1997 | 2 | 0 | 2 |
| 1998 | 2 | 0 | 2 |
| 1999 | 0 | 3 | 3 |
| 2000 | 1 | 0 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 1 | 3 | 4 |
| 2003 | 1 | 1 | 2 |
| 2004 | 1 | 2 | 3 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 5 | 5 |
| 2008 | 1 | 2 | 3 |
| 2009 | 1 | 7 | 8 |
| 2010 | 1 | 2 | 3 |
| 2011 | 1 | 3 | 4 |
| 2012 | 1 | 10 | 11 |
| 2013 | 0 | 2 | 2 |
| 2014 | 0 | 6 | 6 |
| 2015 | 1 | 4 | 5 |
| 2016 | 1 | 3 | 4 |
| 2017 | 0 | 3 | 3 |
| 2018 | 1 | 3 | 4 |
| 2019 | 0 | 2 | 2 |
| 2020 | 0 | 6 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Markov Chains" by people in Profiles.
-
Mattingly TJ, Love BL. Changes in Cost-Effectiveness for Chronic Hepatitis C Virus Pharmacotherapy: The Case for Continuous Cost-Effectiveness Analyses. J Manag Care Spec Pharm. 2020 Jul; 26(7):879-886.
-
Konapala G, Mishra AK, Wada Y, Mann ME. Climate change will affect global water availability through compounding changes in seasonal precipitation and evaporation. Nat Commun. 2020 06 23; 11(1):3044.
-
Anderson BR, Gotlieb EG, Hill K, McHugh KE, Scheurer MA, Mery CM, Pelletier GJ, Kaltman JR, White OJ, Trachtenberg FL, Hollenbeck-Pringle D, McCrindle BW, Sylvester DM, Eckhauser AW, Pasquali SK, Anderson JB, Schamberger MS, Shashidharan S, Jacobs JP, Jacobs ML, Boskovski M, Newburger JW, Nathan M. Registry-based trials: a potential model for cost savings? Cardiol Young. 2020 Jun; 30(6):807-817.
-
Brothers TE, Todoran TM. Permanent inferior vena cava filters offer greater expected patient utility at lower predicted cost. J Vasc Surg Venous Lymphat Disord. 2020 07; 8(4):583-592.e5.
-
Li Y, Bandyopadhyay D, Xie F, Xu Y. BAREB: A Bayesian repulsive biclustering model for periodontal data. Stat Med. 2020 07 20; 39(16):2139-2151.
-
Lawson AB. NIMBLE for Bayesian Disease Mapping. Spat Spatiotemporal Epidemiol. 2020 Jun; 33:100323.
-
Napier G, Lee D, Robertson C, Lawson A. A Bayesian space-time model for clustering areal units based on their disease trends. Biostatistics. 2019 10 01; 20(4):681-697.
-
Bhingare A, Sinha D, Pati D, Bandyopadhyay D, Lipsitz SR. Semiparametric Bayesian latent variable regression for skewed multivariate data. Biometrics. 2019 06; 75(2):528-538.
-
Landeros A, Stutz T, Keys KL, Alekseyenko A, Sinsheimer JS, Lange K, Sehl ME. BioSimulator.jl: Stochastic simulation in Julia. Comput Methods Programs Biomed. 2018 Dec; 167:23-35.
-
Nguyen E, Coleman CI, Kohn CG, Weeda ER. Ranolazine in patients with type 2 diabetes and chronic angina: A cost-effectiveness analysis and assessment of health-related quality-of-life. Int J Cardiol. 2018 Dec 15; 273:34-38.